205 related articles for article (PubMed ID: 34494025)
1. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation.
Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Roh JW; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Di Germanio C; Rizvi N; Stone M; Simmons G; Dumont LJ; Allen AM; Lockwood S; Pollard RE; de Assis RR; Yee JL; Nham PB; Ardeshir A; Deere JD; Patterson J; Jain A; Felgner PL; Iyer SS; Hartigan-O'Connor DJ; Busch MP; Reader JR
bioRxiv; 2021 Sep; ():. PubMed ID: 34494025
[TBL] [Abstract][Full Text] [Related]
2. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.
Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Roh JW; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Di Germanio C; Rizvi N; Liu H; Ma ZM; Stone M; Simmons G; Dumont LJ; Allen AM; Lockwood S; Pollard RE; Ramiro de Assis R; Yee JL; Nham PB; Ardeshir A; Deere JD; Jain A; Felgner PL; Coffey LL; Iyer SS; Hartigan-O'Connor DJ; Busch MP; Reader JR
PLoS Pathog; 2022 Apr; 18(4):e1009925. PubMed ID: 35443018
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma.
Deere JD; Carroll TD; Dutra J; Fritts L; Sammak RL; Yee JL; Olstad KJ; Reader JR; Kistler A; Kamm J; Di Germanio C; Shaan Lakshmanappa Y; Elizaldi SR; Roh JW; Simmons G; Watanabe J; Pollard RE; Usachenko J; Immareddy R; Schmidt BA; O'Connor SL; DeRisi J; Busch MP; Iyer SS; Van Rompay KKA; Hartigan-O'Connor DJ; Miller CJ
Microbiol Spectr; 2021 Dec; 9(3):e0139721. PubMed ID: 34817208
[TBL] [Abstract][Full Text] [Related]
5. Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.
Körper S; Jahrsdörfer B; Corman VM; Pilch J; Wuchter P; Blasczyk R; Müller R; Tonn T; Bakchoul T; Schäfer R; Juhl D; Schwarz T; Gödecke N; Burkhardt T; Schmidt M; Appl T; Eichler H; Klüter H; Drosten C; Seifried E; Schrezenmeier H
Transfus Med Hemother; 2021 May; 48(3):137-147. PubMed ID: 34177417
[TBL] [Abstract][Full Text] [Related]
6. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
7. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
[TBL] [Abstract][Full Text] [Related]
8. A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma.
Wouters E; Verbrugghe C; Devloo R; Debruyne I; De Clippel D; Van Heddegem L; Van Asch K; Van Gaver V; Vanbrabant M; Muylaert A; Compernolle V; Feys HB
Transfusion; 2021 Oct; 61(10):2981-2990. PubMed ID: 34498761
[TBL] [Abstract][Full Text] [Related]
9. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
[TBL] [Abstract][Full Text] [Related]
10. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19.
Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A
Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710
[TBL] [Abstract][Full Text] [Related]
12. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
13. Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.
Lin YJ; Evans DH; Robbins NF; Orjuela G; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
Microbiol Spectr; 2022 Oct; 10(5):e0281122. PubMed ID: 36125288
[TBL] [Abstract][Full Text] [Related]
14. Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors.
Annen K; Morrison TE; DomBourian MG; McCarthy MK; Huey L; Merkel PA; Andersen G; Schwartz E; Knight V
Transfusion; 2021 Apr; 61(4):1148-1159. PubMed ID: 33452828
[TBL] [Abstract][Full Text] [Related]
15. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
16. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
17. Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.
Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Roh JW; Elizaldi SR; Allen AM; Muecksch F; Lorenzi JCC; Lockwood S; Pollard RE; Yee JL; Nham PB; Ardeshir A; Deere JD; Patterson J; Dang Q; Hatziioannou T; Bieniasz PD; Iyer SS; Hartigan-O'Connor DJ; Nussenzweig MC; Reader JR
PLoS Pathog; 2021 Jul; 17(7):e1009688. PubMed ID: 34228761
[TBL] [Abstract][Full Text] [Related]
18. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants.
Di Germanio C; Simmons G; Thorbrogger C; Martinelli R; Stone M; Gniadek T; Busch MP
Transfusion; 2022 Mar; 62(3):563-569. PubMed ID: 35129839
[TBL] [Abstract][Full Text] [Related]
20. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
